

2021

ANNUAL REPORT



børne cancer fonden

Foundation information

The foundation

Børnecancerfonden
Vester Farimagsgade 1, 3rd floor
DK-1606 Copenhagen V

boernecancerfonden.dk

CVR no. 18 40 34 98
Established: 27 December 1994
Head office: Copenhagen
Financial year: 1 January - 31 December

Patron

Ghita Nørby, Actress, The Royal Danish Theatre

CEO

Marianne Benzon Nielsen

Board:

Professor, Dr. Med., Christina E. Høi-Hansen, Chairman
CEO, Jens Bjørn Andersen
Medical Senior Project Manager, Ph.D., Thomas Leth Frandsen
Professor, Dr. Med., Anja Bisgaard Pinborg
Professor, Dr. Med., Søren Rittig
Aut. Cand. Psych., Michael Schiøth, Parent Representative
Attorney, Morten Stadil
Commissioner on the board, Bubber

Science Committee

Former Pro-Dean of Research, Dr. Med., Ole Steen Nielsen
Medical specialist, Ph.D., Arja Harila-Saari
Professor, Ph.D., Ulrik Lassen
Chief Physician, Ph.D., Lars Kjeldsen
Professor, Dr. Med., Cai Grau

Secretariat

Vester Farimagsgade 1, 3rd floor
DK-1606 Copenhagen V
Telephone: +45 35 55 48 33
Bank: Danske bank

Auditors

PricewaterhouseCoopers
Statsautoriseret Revisionspartnerselskab
Strandvejen 44
DK-2900 Hellerup



Thank you



børne
cancer
fonden

Read more at boernecancerfonden.dk



We are members of



Contents

Editorial: An amazing year, despite everything	4
Børnecancerfonden 2021 in figures.	5
CEO: Proud and humble - THANK YOU	6
Key figures	7
Associations, companies, collections and foundations	8
Research	
Scientific grants for research	10
Research status and future challenges.	12
From chemo brain to my brain	14
Grants	
A much-needed boost of energy to daily life	17
Grants have a positive impact.	17
Siblings	17
Continuation school grants.	17
Family support	
Solid support to families during and after treatment.	18
Rehabilitation camp: When illness makes you stronger	18
FAMOS.	18
MusikBeRiget - music as psychological therapy	18
In a holiday house with the whole family.	19
Palliative initiative, for children and young people with cancer	19
RESPECT: Children need other children.	19
Living life as a youth with cancer	19
Our partners	
To name but a few	20
MakVærket	20
Odeno	20
Flying Tiger Copenhagen.	20
Team Rynkeby	23
#Gribbolden.	23
Cool cars and happy children	24
FodboldtrøjeFredag	25
Collections	
Emily Salomon is making a difference	26
Stigminoen	26
Cancerlivfonden	27
Chau Hoi Shuen Foundation Limited, Hongkong	27
Statements	
Management statement	29
Independent auditor's statements	30
Annual accounts 1 January - 31 December 2021	
Profit and loss account	32
Balance sheet.	33
Notes.	35

An amazing year, despite everything

In 2021, we once again received many applications for important research projects and other initiatives aimed at ensuring an ongoing positive development for children with cancer. The result for the year is one of our best since the foundation was established in 1995, and this year we have been able to distribute more than DKK 49 million. This is not least due to all of you who support our cause - and who have faithfully done so over the course of the year despite the corona pandemic and other circumstances. Thank YOU SO MUCH.

We are proud to have paved the way for solid business areas that have created the foundation for the results that we see in terms of survivability and new methods of treatment. Today, there is among other things being conducted research on methods of treatment such as immunotherapy and what impact genes have on the disease occurring. Six out of seven children survive child cancer.

However, this does not mean that our work is done, it only means that results are achieved when you are tirelessly over many years working with providing a stable level of support to a research area such as child cancer. It should also be emphasised in this context that child cancer is still the disease that children are most likely to die from each year. There are also types of child cancer such as brain tumours and DIPG (Childhood Diffuse Intrinsic Pontine Glioma) where the mortality rate is 100 %.

Over the years, intensified chemotherapy treatments have had a positive impact on survivability, but for some, the price has been significant side effects both in the short and long run. The challenges that children and young people might have include memory and concentration issues when they return to school after their treatments are completed. The MyBrain research project is focused on this very issue, and you can read more about this and other selected research projects later in the report.

The focus of Børnecancerfonden is mainly to support research in child cancer, and since 1995 we have distributed DKK 469 million for this purpose. However, continuing to fund the research is critical in the years ahead. And in this context, it is great news that other actors have also joined the fight and are supporting children so that together we can continue to see significant results for children with cancer and their families. In addition, the rules for legacies have meant that we have been able to distribute more funds directly from legacies to our general purpose - previously, the legislation meant that the funds had to be registered as nominal capital.

We are proud that in Denmark today we have become so good at our work that we have Danish researchers sitting at the ends of the tables in important international research forums which, among other things, ensures that children in Denmark benefit from the cutting edge of research in this area. We are working towards ensuring that children with cancer survive and have a life without lasting complications - both physical and mental. Therefore, we also support families both during and after treatment. When a child gets cancer it is a long and difficult process, so help and support is needed along the way. You can read more about the foundation's support for families later in the report.

Thank you to those of you who are already supporting this effort with the important financing aspect and thank you to those of you who are working to find answers in medical science and to all of you who are always there for the children and their families.




Christina Høi-Hansen
Chairman of the Board,
Professor, Dr.Med.



Børnecancerfonden 2021 in figures



Income development (DKKm)



Proud and humble - THANK YOU

I am both proud and humble to be able to present one of the best collection results for Børnecancerfonden, amounting to DKK 67 million after two years of the corona pandemic where many of our supporters have faced difficult times. So I would like to begin by expression how grateful we are for this. The income from events increased from 2020 to 2021, while other income was around the same as the high result for 2020.

Even though children with cancer have also been impacted by the corona pandemic, the children have not felt the impact on the illness they are fighting against. The support aspect has perhaps never been greater, as many years of research funding has provided important results that are already directly benefitting the children. The research has also become more refined and thus more expensive than before. The positive development in results is a motivating factor and something we need to ensure continues - because there is still a great need for it.

I have personally worked closely with families in the child cancer hospital wards and seen up close and personal what it means being a child with cancer and how it impacts the entire family. It is heart breaking how violent a child cancer process is.

In order to continue being able to finance solid research, we have worked in a targeted manner in developing the foundation and our approach to the highly competitive collection space that we operate in. In this context, it is great that we still have a lot of good and loyal partners working along for the journey, for example, Team Rynkeby, Sportscar Event, Golf Rock and Danmark Rundt Team Bodenhoff. And we are also fortunate that new many new partners are joining us. Everyone is making a critical contribution.

We need to ensure that Børnecancerfonden's development is always carried out with a focus on being able to distribute maximum amounts for our purpose each year. This means that what might have been able to be completed in a short time frame in a commercial company takes a little longer for us. But I think that is how it should be when working with donated funds.

Our cost levels in 2021 were low due to a low level of activity and more moderation in our collection costs. The corona pandemic also resulted in events for children and their families having to be cancelled.

The market situation and the global uncertainty makes it even more important to have a stable focus on children with cancer. My goal is that children with cancer in Denmark should have the best prerequisites and opportunities. Therefore, the growing international research partnerships are important, and I am proud that we have contributed to Danish researchers now having influential roles in the international research environment.

We are looking forward to continuing to work together on what we are passionate about - helping children with cancer and their families.



Marianne Benzon Nielsen
CEO



Key figures

The foundation's purpose

Børnecancerfonden's purpose is to work with children with cancer. The work is divided into three focus areas: Child cancer research, family support and spreading awareness.


Incoming funds and how they are used

Børnecancerfonden's incoming funds and how they are disposed of it 2021 compared to the two years before can be highlighted as follows:

Key figures, last 3 years	2021	2020	2019
Amounts in thousands	DKK	DKK	DKK
Donations, legacies, contributions and collections	28,266	28,471	21,918
Income from events	31,511	28,564	33,592
Contribution from public allocation funds to cover costs	1,705	1,679	1,507
VAT compensation	978	600	384
Return on Foundation holdings (net)	4,524	3,431	6,067
Total income	66,984	62,745	63,468
Legacies reserved for nominal capital	33	7,248	6,355
Costs from income-generating activities	9,657	11,055	9,895
Profit/loss for the year	57,294	44,442	47,218
Administration costs	2,674	2,705	2,648
Expenses for objective-related activities	3,579	3,413	4,955
Profit/loss for the year	51,041	38,324	39,615
Allocations/grants for the year	49,527	33,776	39,540
Reserved for later allocation	14,222	11,547	6,611
Key figures			
Profit margin	85	69	72
Administration percentage	4.3	4.6	4.6
Objective percentage	6	6	9
Solvency ratio	71	71	69

Income in 2021

Events/collections	47.0 %
Legacies allocated to nominal capital	0.1 %
Gifts/contributions	42.1 %
Return on foundation holdings	6.8 %
Public funds	4.0 %



Associations, companies, collections and funds that have cooperated with or supported Børnecancerfonden in 2021 with DKK 100,000 or more



Danske Spil



Holberg Fenger Gruppen

Udvikling for fremtiden

Sparinvest



MakVærket



Arvid Nilssons Fond | Civilingeniør Frode V. Nyegaard og Hustru's Fond | Chau Hoi Shuen Fondation Limited
 Cancerlivfonden | Svend Johansen | MICA Fonden | Edith og Søren Kiilerich Hansens Familiefond
 Jørgen Hesse | Helsefonden | Sonja Hansen | Orients Fond | John og Birthe Meyer Fonden | Stigminoen
 Aage og Johanne Louis Hansens Fond | Solveig Susanne Matzen | Ole Frederiksens Familiefond
 Gangstedfonden | Henrik Henriksens Fond | Domino Møbler | Det Obelske Familiefond | Lindebjerg Skolen
 Støtteforeningen Bingo Banko Fredericia | Kronprins Frederiks og Kronprinsesse Marys Fond
 Marie-Helene Andersens Fond | Ilse H Knudsen | Hoffmann og Husmans Fond | Fabrikant Chas. Otzens Fond
 Det Nissenske Familiefond | Direktør J.P.A. Espersen og hustru, fru Dagny Espersens Fond | Amagria ApS



“

A cancer diagnosis is one of the worst things that can happen to us, and unfortunately, it can also happen to our precious children. Therefore, research is needed so that at length we can prevent child cancer and support is also needed for those families who already have children with cancer. I am happy to contribute to the critical work that **Børnecancerfonden** does via my work on the foundation's board.”

Jens Bjørn Andersen, CEO of DSV and member of the board of Børnecancerfonden

Research

Scientific grants for research

Once again in 2021, Børnecancerfonden received many solid and qualified research applications that our Scientific Committee assessed with great interest. We ended up allocating more than DKK 40 million to research and research infrastructure. Below, you can see some of the projects that received support. And with this support there is also a big thank you for the huge and important work that we are all so passionate about.

Better diagnostics and treatment for connective tissue cancer

The recovery rate for connective tissue cancer is 60 % in general but only 10 % if it has spread. And then there are difficult late complications afterwards. The national SNITCH project is working on improving both diagnostics and treatments and reducing the late complications after connective tissue cancer.

Lisa Lyngsie Hjalgrim, Chief Physician, Rigshospitalet – allocated **DKK 2,200,000**

What CAR-T cells mean for relapse

Immunotherapy has increased the survivability rates for children with the type of leukaemia called B-ALL significantly, but there is still a relapse rate of approximately 50 %. In a Nordic partnership, researchers will study the impact of the number of CAR-T cells and their types and functions and the patient's general immune system have on relapses. One of the objectives is to identify high-risk patients.

Katrine Kielsen, Reserve Doctor, Rigshospitalet - allocated **DKK 900,000**

mRNA profiles are to prevent relapses of tumours in the central nervous system

Researchers will study and map mRNA profiles in blood platelets for, among other things, monitoring to see if there is a way of getting an early diagnosis for a potential relapse for children with tumours in their central nervous systems.

Mimi Kjærsgaard, Department Doctor, Rigshospitalet - allocated **DKK 1,126,083**

A more precise classification of the AML type of leukaemia

In a global partnership through the Childhood AML network, researchers will study genetic changes among children with the AML type of leukaemia.

So far, we have the most experience with the changes that occur in adults with AML, but this new research project will now investigate children. The goal is to get better treatment results with less side effects.

Henrik Hasle, Professor and Chief Physician, Aarhus University Hospital – **allocated DKK 2,000,000**

The members of the Scientific Committee are:

- Dr. Med., former Pro-Dean of Research, Ole Steen Nielsen, Aarhus University
- Medical Specialist, Ph.D., Arja Harila-Saari, Karolinska Institutet
- Professor, Ph.D., Ulrik Lassen, Rigshospitalet
- Chief Physician, Ph.D., Lars Kjeldsen, Rigshospitalet
- Professor, Chief Physician, Dr. Med., Cai Grau, Aarhus University Hospital

Three important initiatives

The participation in the MAPPYACTS 2 project, started in France, will improve the treatment for children and young people with resistant or relapsed cancer via three initiatives: 1) supplementary clinical and molecular biology research, 2) significantly improved clinical interpretations of advanced molecular analyses and 3) better advisory services about targeted treatment of their cancer.

Karsten Nysom, Chief Physician and Dr. Med., Rigshospitalet - allocated **DKK 2,900,000**

Research in asparaginase is to prevent severe side effects

The enzyme called asparaginase is an important part of the treatment of the type of leukaemia called ALL, also when the disease has spread to the central nervous system. However, the enzyme has a number of side effects, including blood clots. The project aims to study two things: the effect of the asparaginase treatment on leukaemia cells in the central nervous system and possible markers in the spinal fluid that can predict the development of blood clots in the brain.

Birgitte Klug Albertsen, Chief Physician, Clinical Associate Professor, Ph.D., Aarhus University Hospital - allocated **DKK 1,500,000**

Measuring late complications after leukaemia

The results from the Adult Life After Childhood Cancer in Scandinavia (ALiCCS) study indicate that children with leukaemia are particularly at risk of developing late complications. The project will measure late complications (long-term and mental) via hospitalisations and the use of medication from existing registries. Late complications are paired up with treatment data to give a more detailed view of side effects and late complications.

Henrik Hasle, Chief Physician and Dr. Med, Aarhus University Hospital – allocated **DKK 500,000**

Physical activities as part of the treatment

Treating children for cancer results in many long periods of hospitalisation and isolation. For the children, this means reduced levels of physical activity, lack of development of their motor skills and possible stunting of their social competences. The “RePlay” project aims to use play and exercise to improve motor development and social skills in children with cancer between the ages of 1 and 5.

Hanne Bækgaard Larsen, Nurse, Ph.D., Research Coordinator and Associate Professor, Rigshospitalet - allocated **DKK 750,000**.

21 newly defined side effects of leukaemia

An international research group headed by a Dane defined the 21 most serious side effects following the treatment of leukaemia. The project will now map the occurrence of these side effects since children die just as frequently from the side effects of treatment as from the actual treatment.

Kjeld Schmiegelow, Professor, Rigshospitalet - allocated **DKK 1,300,000**

Side effects from stem cell transplants

Stem cell transplant can lead to side effects that may be acute life threatening and lead to severe late effects. However, not all children benefit from the medicine that can potentially help. The international project will find a method to limit this group and improve the diagnosis of the side effects by combining clinical diagnostic criteria with bio markers for vessel damage.

Klaus Gottlob Müller, Professor, Rigshospitalet - allocated **DKK 825,000**

Analysis of children’s genes


STAGING was launched in 2016, and since then there has been worked on finding mutations in the genes of children with cancer in order to explain why the disease occurred. It is critical to ensure that STAGING’s infrastructure remains so that there can be ensured a continuing access to genetic data for research.

Kjeld Schmiegelow, Professor, Rigshospitalet - allocated **DKK 460,000**

What the funds were spent on

2021 income

Research	62.4 %
Family support	17.8 %
Information	0.7 %
Obligatory nominal capital reserves	0.1 %
Costs from income-generating activities	14.7 %
Administration	4.3 %



Research status and future challenges

By Professor Kjeld Schmiegelow, Rigshospitalet, and Professor Henrik Hasle, Aarhus University Hospital.

For the past half century, we have seen a very positive development in the treatment of most kinds of child cancer. Whereas previously the treatments had no or only a limited effect, they now ensure that more than 80 % of children survive. This development is due to more precise diagnostics, new methods of treatment and more individualised treatments that increase the chances of recovery and minimise serious side effects.

More precise diagnostics

New biological analyses, including genetic ones, have improved diagnostics. Partly by identifying the children who have a congenitally higher risk of developing cancer (10-15 % of all patients) and partly by mapping the abnormal biology of cancer cells. The latter has led to the development of new treatments that specifically target the disrupted cellular biology so that more patients can become healthy again. Today, all children with cancer are offered to have their full genome studied to find out if they are particularly genetically disposed to developing cancer. And when treatments fail, there is completed a comprehensive mapping of the genomes of cancer cells to reveal whether new medicine can target the cells' abnormal biology.

New treatments

The Danish child cancer hospital wards are participating in a great deal of international studies where new and improved treatments are being tested. Many of the new treatments for children with treatment-resistant cancer, including relapsed cancers, are tested in the Danish "Department for new medicine for children with cancer" at Rigshospitalet. Some of the treatments have been developed to treat cancer in adults, as it has been revealed that the same abnormal cancer biology can be found in patients with - at first glance - dissimilar diseases, such as neuroblastoma or lymph node cancer in children. This has meant that there is rapidly being developed new medicines that can benefit children with cancer.

A particular focus area is immunotherapy. This may include medications that help the immune system spot cancer cells or immune system cells that are "trained" or genetically manipulated in a laboratory to attack cancer cells. Immunotherapy is associated with other and often less serious side effects than traditional chemotherapy.

However, so far only a few children can become candidates for immunotherapy. Candidates may be children with rare growths or children with relapsed leukaemia. More research is needed to determine how more children can benefit from immunotherapy and whether it in the future can replace some of the familiar treatments.

Individualised treatment

We have become more effective at measuring the effects of treatments using advanced laboratory methods. With PCR and flow cytometry, it is possible to measure the amount of residual disease in leukaemia patients and new scanning methods can be used on solid growths to spot more details while the use of contrast substances show tumour activity.

The more precise measurement of treatment efficiencies is the foundation for individualising treatments. With an individualised treatment, it is ensured that the strongest treatments with the highest risk of severe side effects is only given to those patients that need it while others can receive more gentle treatments with less side effects.

The individual response to chemotherapy is something that we do not know a lot about. Even though two children of equal size get the same dosage of medicine, their bodies can react in very different ways. In this area, Denmark has been a leading player via a number of international studies that, among other things, reveal how changes to patients' genomes impact their absorption of medicine. Measuring the levels of medicine and its digestive products allow for an adaptation of chemotherapy doses to individual patients and this provides a better balance between effects and side effects.

Even though we have come a long way, we still need to develop better diagnostics and new treatments. The

national and Nordic collaboration on trying out new medications has allowed more children to have the opportunity to participate in new medical trials and Denmark is one of the countries in Europe that performs the best in this area. Unfortunately, cancer treatments are also associated with the risk of many acute and late complications. For acute lymphatic leukaemia (ALL), the recovery rate is so high that of the deaths that occur, around half are due to side effects of the treatment. Therefore, there is a major focus on ensuring the best supporting treatment when there are serious side effects while also selecting patients carefully so that only those with the most aggressive cancers get the most intensive treatment.

On top of this, many of the recovered patients have late complications. This may be in the form of reduced kidney

and heart function, loss of hearing or visual impairments. Danish and Nordic researchers are continually mapping the extent of the problem and pointing towards potential parts of the treatment that are responsible for late complications and which can play a role in future individualised treatments. Psycho-social side effects can impact the recovered patients' ability to have a normal life as teenagers and adults. To ward off these side effects and strengthen the individual patients and their networks, there is a need for long-term research and efforts from many professional groups, including schools.

In Denmark, cancer is unfortunately responsible for every fifth death in children above the age of 1. When recovery is not possible, the palliative care is particularly important, including having the option to die in one's own home.



From chemo brain to my brain

By Chief Physician Lisa Lyngsie Hjalgrim, Rigshospitalet, and Researcher Barbara Nordhjem, Rigshospitalet

Is it difficult to remember? Is it possible to concentrate when returning to school or one's studies? And how does one train the brain? These are the kinds of questions that parents and young cancer patients ask the healthcare workers. But there are no clear answers.

Children and young people often report that they have difficult remembering and concentrating when their treatments are complicated and they return to their everyday lives. This phenomenon is called "cancer-related cognitive impairment" or, more colloquially, "chemo brain". As more and more lives are saved from better cancer treatments, it is important to also get a better understanding of possible cognitive late complications. In 2020-2021, the MyBrain research project was allocated DKK 2,700,594 from Børnecancerfonden to monitor the brain during the whole process from the first diagnosis to the recovery.

"The goal of MyBrain is to uncover which cancer patients have changes in their cognitive functions and what might be causing those changes. The results can be used to prevent reduced heart function and to support patients with cognitive difficulties so that they can return to school and their everyday lives." So says Lisa Lyngsie Hjalgrim, Chief Physician and the senior MyBrain researcher.

Patient-driven research

One of the places that MyBrain originated was during a theme night in Kræftværket, which is a network for young people with cancer. Here, the patients specifically asked for more knowledge about cancer and cognition. Subsequently, a group of doctors, nurses and researchers at Rigshospitalet began working on assembling an interdisciplinary team of specialists that contribute with different scientific approaches.

And it is not just the young people in Kræftværket that are asking for more information. Leukaemia survivors and their parents often report that cognitive difficulties are one of the late complications that concern them the most. The ALL-STAR research project (which is also supported by Børnecancerfonden) is in the process of studying a large number of late complications from survivors treated for acute lymphocytic leukaemia (ALL). Preliminary results show that 14 % of survivors report difficulty concentrating (among their peers without cancer, this figure is 5 %). And both survivors and their parents also identify cognitive difficulties as one of the big challenges.

ALL-STAR

ALL-STAR is a research project that uncovers late complications in children and young people with the most frequent kind of child cancer, acute lymphocytic leukaemia (ALL).

The developing brain is special

There is a serious lack of research when it comes to monitoring the young brain from the diagnosis stage to the end of a treatment. Currently, most of the studies on cancer and cognition are structured as cross-sectional studies of survivors treated in adulthood. These studies do not tell us enough about children and young people where the frontal lobes are still being developed and where learning and change happens at a completely different pace.

"I am proud to be part of a project based on young patients' own wishes for research. They are in a phase of their lives where lots of development is going on and where the brain is facing a lot of demands, and they can also be more vulnerable. We simply do not know how the brain and its many functions are impacted in children and young people during and after cancer treatments." Barbara Nordhjem, MyBrain researcher and Ph.D. in cognitive neuroscience.

From diagnosis to survival

MyBrain stands apart from other studies because it monitors children and young people throughout the entire process of the disease and across diagnoses. The goal is to recruit 100 children and young people aged 7-24 who have cancer and 100 healthy people for the control group. The project uses many different methods to investigate cognitive impairment and the potential underlying mechanisms. Blood markers related to brain functions are analysed, the brain



is scanned and various tasks need to be solved to get an insight into cognitive domains such as memory, language, problem-solving ability and concentration. In the existing research, there is typically either a focus on the molecular mechanisms and chemotherapy's impact on the body or on stress or psychological aspects. The combination of different angles to study the same problem will be another step forward in the research.

In addition, in another partial study the researchers are mapping different cognitive functions in leukaemia survivors who received treatment during childhood. This has led to new knowledge about late complications many years after a completed course of treatment while it also allowed the researchers to learn more about what specific cognitive areas such as language or memory are particularly vulnerable.

There is hope for a better understanding and cognitive rehabilitation

MyBrain is off to a good start and has included the first newly diagnosed patients and over 50 leukaemia survivors. The researchers recently attended a network meeting in Kræftværket where it all began. Here, the young people stated that it was very important to them that they had been heard and that they were hoping for more information about cognitive challenges when their treatments started.

“As a patient, it is important that you get a better understanding of what is going on. After all, no one can really understand what it is like to receive chemotherapy. I had actually felt a bit lost, and it was only a long time afterwards that I found out that there were actually other people in the same boat.” That was how one of Kræftværket's users put it.

The hope is that the research will both provide families and healthcare workers with more of the knowledge that is being asked for. At the same time, studies like MyBrain are important when it comes to offering the right support and training specific brain functions.

**In 2014,
Børnecancerfonden
allocated DKK
1,680,000 to
Kræftværket**



Grants

A much-needed boost of energy to daily life

Grants for psychological help

Allocated: DKK 824,000

Grants for continuation school stays

Allocated: DKK 260,000

Grants for care

Allocated: DKK 920,000

Grants have a positive impact

Børnecancerfonden has allocated approximately 180 'special treat' grants each year for the past few years. The grant is not for any specific purpose and can be used for whatever would make the individual children happiest. When a child gets cancer, it often requires that one of the parents take time off with sickness benefits. The normal everyday life of going to work is put on pause. This can easily mean that the family's finances get tight. A grant can therefore remove one of the worries that the parents have.

Siblings

It is often seen that the healthy siblings do not want to 'get in the way' and might withdraw from the family. As something new, in 2021 the foundation chose to set up a new type of grant: the continuation school grant. A continuation school grant can be applied for on behalf of the child - but also the siblings.

It makes a lot of sense that siblings of a child with cancer also need a helping hand and someplace to be themselves - and the continuation school grant can help them with this.

Continuation school grants

In 2021, we have allocated funds to more continuation school grants. This is particularly due to the efforts of Tine and Flemming Fenger. Through Holberg Fenger Invest, under the name of Simon, over the last two years the couple have donated DKK 450,000 and are expecting to continue donating.

The family has experienced up close and personal what it means to have a child with cancer. Fortunately, their son Simon is cured today and lives a normal adult life without serious late complications after his cancer. Tine and Flemming Fenger have a strong desire to support children with cancer as directly as possible, which is why an earmarked grant is a great match for their donations.

Tine and Flemming Fenger are an invaluable part of the forces supporting children. As Tine tells it:

"When my son was sick and receiving treatment, I remember that some of his friends showed up at Rigshospitalet and spent a lot of hours together with Simon. Even if Simon had asked them not to visit and hadn't responded to their calls. They just showed up and became a huge support for all of us. Today, 10 years later, they are still his best and closest friends. The quote from Winnie the Pooh hits the spot: "Friendship is the best gift you can get."

Family support

Solid support to families during and after treatment

When a child gets cancer, family life becomes a challenge - and the everyday life of the sick child and all his or her loved ones changes as well. Børnecancerfonden is offering support via a number of offers for families facing what is probably their most difficult circumstances. Some of these offers are presented on the following pages, and the financial support given for 2021 is also stated.

Rehabilitation camp: When illness makes you stronger

Denmark's only activity-based rehabilitation camp, Cool Camp, is held under the heading "when illness strikes".

This is a place where young people and their families can have fun with others who have are or have been going through similar experiences as themselves. The various youth camps are set up to help the children and young people with cancer grow stronger and improve their self esteem and give them hope and faith in the future.

Each year, around 20 trained volunteers help to facilitate the activities and there are also healthcare workers specialising in child cancer present. After the camp, the young people and their siblings are given the opportunity to participate in a mentor programme aimed at helping them implement the tools covered in the camp in their everyday lives - so that they emerge stronger.

Børnecancerfonden has supported the project since the beginning of 2014 and allocated **DKK 1,898,536 in 2021**.

3 camps

- For young people with cancer, ages 12–17
- For siblings, ages 12–17
- For families with children, ages 6-12

FAMOS

Børnecancerfonden is now offering family-oriented support at home in the form of talks with psychologists. The goal is to help families manage their lives, feelings and each other during or after a tough period of child cancer in the family.

The psychologist will visit them at home and talk to both adults and children. There is a specific manual with the offer and a number of cognitive treatment methods and videos with examples that can help the family. In particular, showing understanding for each other's reactions during the process is highly beneficial for everyone. One family recounts:

"We were each living in our own bubbles. The husband and siblings were home and could not visit the hospital, as our son was at Rigshospitalet and the corona pandemic restrictions prevented visits. With FAMOS, we could all be heard and seen by a professional who could bring us together and guide us in our "upside down" world. The fact that the psychologist could come to us made it a safe and easy experience during a confusing time. If she had not come to us, I do not think that everyone would have accepted the offer of psychological help."

MusikBeRiget - music as psychological therapy

The music therapy project called "MusikBeRiget" led by violinist Lisbeth Sagen gives children hospitalised with cancer a break from their disease. The children can get help dealing with difficult feelings via classical and rhythmic live music at the hospital.

Børnecancerfonden has supported the project with around DKK 3 million since it started, and most recently allocated **DKK 1,161,000 to it in 2021**.

Børnecancerfonden's holiday cottages



In a holiday house with the whole family

Børnecancerfonden's three holiday cottages are lent out year-round to families who have children with cancer, and this allows the whole family to get some room to breathe and gather new energy for their everyday lives with a child with cancer. The holiday cottages are in beautiful natural areas in Blokhus in northern Jutland and in Dronningmølle in northern Zealand. Families with children and young people going through active treatments get preferential treatment when it comes to being allowed to borrow the cottages.

Palliative initiative, for children and young people with cancer

An interdisciplinary and coordinated initiative aimed at expanding and improving the palliative care available to children and young people with cancer - attached to Rigshospitalet. The project is to ensure that the child or young person and their families have their needs and wishes fulfilled. They are therefore offered a coordinated and coherent high-quality interdisciplinary process with equal access for all.

Palliative care coordinator, Line Dyrgaard, Rigshospitalet
Allocated **DKK 250,000 in 2021.**

RESPECT: Children need other children

RESPECT started out as a research project at Rigshospitalet and is now an offer for all children with cancer in Denmark. Several years of cancer treatments with absences from both school, friends and leisure activities - and often with social challenges as a result - is a hard pill to swallow for a child. The RESPECT project arose when nurse, Ph.D., research coordinator and Associate Professor Hanne Bækgaard Larsen,

Rigshospitalet, asked the question: "How can we bring the friends of the child to the child when the child cannot come to them?" It was an unlikely scenario. But it succeeded - and it is now what we call the RESPECT project. Among other things, RESPECT is an ambassador project where children with cancer have their healthy friends visit them at the hospital - even though they are in isolation. In addition, the child's classmates and teachers are taught about child cancer. It is important for the children to be with their friends while they are hospitalised. This maintains their relationships, creates quality of life and preserves a kind of normality in an everyday life that is anything but normal. The children also get to maintain some of their social and academic attachments and the project and the visits improve the child's quality of life and the rehabilitation after the end of the treatment becomes easier.

Børnecancerfonden has supported the project with just under DKK 15 million since it started in 2012, and most recently allocated **DKK 3,381,200 to it in 2021.**

Living life as a young person with cancer - evaluation and anchoring of the 'Unge-tjek' ('Youth check') programme.

Based on a qualitative and quantitative evaluation, the Unge-tjek programme will be further developed and expanded. Unge-tjek is a tailored and individualised psycho-social support offer for 12 to 18-year-olds at Rigshospitalet that is managed by doctors, nurses, social workers, psychologists, pedagogues and teachers.

Project nurse and youth coordinator, Margrethe Fogh Nielsen, Rigshospitalet. Allocated **DKK 257,556 in 2021.**

Our partners

To name but a few

All around Denmark there are passionate individuals, volunteers and companies that make a real and admirable difference every day. This is deeply appreciated and extremely important. It is only with this kind of support that we are able to help the children. Some partnerships go all the way back to the establishment of the foundation. Other partnerships are brand new. Some partnerships result in large donations, others bring in a lot of passionate helpers and other partnerships are more small scale. What all these partnerships have in common is that they - together with a lot of volunteer work - collect money and create a lot of good experiences. These experiences awaken feelings in us, the families and thousands of people in Denmark and create good memories.

MakVærket

It began as a hobby for Jørgen Troelsen, who needed something positive to focus on after losing his daughter in 2018. Today, it is a company with three owners and a team of volunteers.

Jørgen started MakVærket as the designer of sewn handbags. 3,000 handbags have been put up for sale, and all of the profits go directly to child cancer initiatives. At the time of writing, MakVærket has collected close to **DKK 500,000** for Børnecancerfonden.

At the beginning of 2022 Jørgen Troelsen lost his own battle with cancer - but MakVærket lives on with Jørgen's spirit and continues supporting children with cancer.

Odendo

An online auction house that helps to make a difference for several good causes - fortunately, one of them is us and children with cancer. Here, people can make a good deal and support good causes at the same time.

Odendo donates 5 % of its revenue to good causes. It is the users themselves that decide which causes they want the 5 % to go to. In 2021, Børnecancerfonden received a cheque from Odendo of more than **DKK 127,472**.



Flying Tiger Copenhagen

September is the international child cancer awareness month - and therefore also an important month where our communication work is intensified.

In 2021, we entered into a partnership with Flying Tiger Copenhagen. The goal of the partnership is to both collect money and generate awareness in all Flying Tiger Copenhagen stores throughout the month of September. Flying Tiger Copenhagen also donated gift packages directly to families at child cancer wards.

All of Flying Tiger Copenhagen's employees and customers succeeded in collecting just under **DKK 900,000** in donations.





Facts about Team Rynkeby

- 2,400 riders and 550 helpers - across 59 local teams in 8 countries
- DKK 18,221,814 was collected by Team Rynkeby to Børnecancerfonden in 2021
- Denmark to Paris - 1,200 km in 7 days. (Though not in 2021 due to the corona pandemic)

Team Rynkeby has collected more than a quarter of a billion Danish kroner to Børnecancerfonden

Team Rynkeby is a very special partner to us. Through a multi-year loyal partnership, Team Rynkeby has been part of making an absolutely vital difference for children with cancer. Since 2002, Team Rynkeby has been focused on collecting money for the children.

Jørgen HK Jepsen, General Manager of Team Rynkeby, explains:

“Wanting to help children with cancer is part of Team Rynkeby’s DNA. We see ourselves as a project that can create light and hope for children and their families when they are hit by one of the worst diseases out there. When we ride on our yellow bicycles, we both try to pedal hard so that we can get in shape and also to attract sponsors that can contribute to funding research. We are trying to be the positive aspect of a malignant disease. We are a community that empowers our participants.”

Would you like to become part of this unique culture?

Jan Petersen, Cost Down Manager at Danfoss, joined Team Rynkeby Sønderjylland in 2015. He was simultaneously happy, proud and slight nervous when he was selected. Thoughts like: “What is going to happen? Can I keep up? Can I even find sponsors?” filled his mind. However, Jan quickly discovered the unique Rynkeby culture.

Today, he is the captain of Team Rynkeby Sønderjylland. Jan has seen for himself what child cancer can do to a family, when the daughter of a couple he was friends with got diagnosed. It impacted everyone in their social circle, and the support from Børnecancerfonden was very important to the family.

“One of the worst things imaginable for a family is when your child becomes seriously ill with cancer or even dies. If I can help make a difference for just a single family via my work as team captain, then it will have all been worth it. The best thing about being

part of Team Rynkeby is that we are part of making a difference. I get so much positive energy from experiencing how, as a team, we collect money from different events, sponsorships from our incredibly generous local companies and, not least, the complete support of our local community,” says Jan Petersen.



#Gribbolden

In 2021, we have run the #Gribbolden campaign for the third year in a row.

Our partners, NENT Group, Select and the trade union 3F, have joined together and donated 5,000 Select Replica Super League footballs as a thank you for a donation of at least DKK 200. In all three years, the demand has been so great that we have run out of footballs in very short order. This partnership has resulted in Børnecancerfonden getting about a million Danish kroner in donations each year.

“Children should not get cancer. It is completely unfair and something we should solve together. We are proud of the partnership and the support that we can give,” says Jakob Frimann Sørensen, Nordic Head of Sports at Nent Group. Besides the monetary donations, the partnership also contributes with exposure on both TV, stream services and social media. Børnecancerfonden and the football get the most cover during the annual Super League matches.

Cool cars and happy children

One of our long-lasting partnerships is with Sportscar Event. Since 2002, Sportscar Event has collected almost DKK 18 million to Børnecancerfonden.

Each year, a group of passionate individuals get together to create an amazing experience:

“Sportscar Event consists of a lot of people who take great pride in making a difference for others. Our mission is to create smiles and joy in children and their families - to give them a much-needed break from a tough everyday life and to allow them to forget illness for a moment. The funds we collect are meant to contribute to child cancer research,” says the Chairman Flemming Chrone.

Sportscar Event is held in three different locations, and it takes place over two days at each location. It includes a day for children which is about helping children with cancer and their families and an audience day where money is collected.

“As an event manager, it is a pleasure to be surrounded by so many volunteers who each year contribute both their time and cars for the purpose. They take time off work and holidays and travel with us around the country to work on Sportscar Event for the benefit of children with cancer. There really is a huge amount of commitment and a sense of community surrounding this important cause,” says Dorte Lassen, Event Manager for Sportscar Event.





FodbolldrøjeFredag

Børnecancerfonden's annual collection day in a partnership with Danske Spil. In September, we held yet another FodbolldrøjeFredag, which translated as 'Football Jersey Friday'. This is a day where all of Denmark puts on a football jersey - not only does it look great, it also helps children with cancer.

Donate, share, participate

That is how easy it is to take part - and fortunately, a lot of people are happy to do so. Because even if you are not a football fan, everyone can be part of making a difference. The collection is easy to take part in; you simply put on your favourite football jersey and share a picture on social media using the hashtag FodbolldrøjeFredag. You can decide for yourself whether you want to support the cause with an optional amount to Børnecancerfonden or just want to spread the good message by posting images of yourself, possibly together with colleagues and friends, wearing a football jersey.

One of the many companies that participated was DSV A/S. CEO of DSV Road

A/S, Simon H. Galsgaard, explains how they participated in this year's collection:

"The event around FodbolldrøjeFredag began during the corona pandemic where a lot of employees were working from home. This was something we could all share - each on our own, and we got a lot of support. Not just from football fans, but also from all of the employees who thought that Børnecancerfonden was, and is, a really great cause to support."

He continues:

"FodbolldrøjeFredag has now become a recurring tradition in the company. Even though the event at our company is employee driven, it is supported by DSB DK A/S, which has chosen to double the amount collected by employees."

From now on, Børnecancerfonden will hold FodbolldrøjeFredag each year together with Danske Spil on the first Friday of March and just this one time per year.

In 2021, we collected **DKK 1,315,964**.

Collections

Many people in Denmark are making their own unique collections as well, from hiking trips, car trips to flea markets and events on social media and much, much more.



Emily Salomon is making a difference

“You think this kind of thing only happens to other people. But it can hit anyone. Even children. That is why it is so important to have an organisation like Børnecancerfonden,” says Emily Salomon Vang, one of Denmark’s biggest influencers.

Emily will never forget the day where the doctor called and said that they should head to Rigshospitalet immediately. The doctor had found a tumour in her son Knud’s stomach, and it was the size of a grapefruit. The next two months consisted of countless examinations, scannings, biopsies, pain medication, probes and finally an operation.

Fortunately, Knud’s tumour was benign, but Emily got to experience what it feels like being in the eye of a hurricane - with the worst uncertainty of all: What if my child has cancer? And that was the experience that made her support the work of Børnecancerfonden.

With more than 67,000 followers on Instagram, Emily has a platform with which she can really make a difference. She has used her voice to support the work of Børnecancerfonden and has collected an entire DKK 85,059 over several collection rounds. “I am so grateful that there is an organisation like Børnecancerfonden. They do not just support child cancer research, they also help impacted families in many different ways. That is why it is so meaningful for me to use my platform to collect donation for Børnecancerfonden,” says Emily.

Stigminoen

“My word is my word, and when I have lost, I have lost.” Stig Tøfting was quoted as saying that. And that is how it went when he lost a bet about who would become the next President of the United States. Tøfting had bet on it being Trump, but as it turned out, Biden won. And the price for losing the bet was a 167 km long walk from his home in Viby to the Danish-German border where the winner, journalist Mirco Reimer-Elster, lives.

This is not the first walk that Stig Tøfting has had to take after losing a bet. Back in 2019, he also had to go out on the Jutland heaths after losing a bet about who would win a football match. It generated a lot of attention, and it was expected that the walk to the German-Danish border would do so as well. Stig Tøfting wanted to use this attention for a good cause, so he chose to collect money for KidsAid and Børnecancerfonden.

With a simple walk, Tøfting managed to engage all of Denmark, both virtually and in the real world. Tøfting invited children with cancer to join him on the walk for as long as they were able. And in other places, random people in Denmark would walk together with Tøfting while others bid on virtual auctions to contribute to the collection. In total, the former Danish national team soccer player managed to collect DKK 1 million to KidsAid and Børnecancerfonden and the money was split evenly between the two organisations.

The walk showed how far you can get with willpower and a positive attitude. And those are two qualities that Stig Tøfting certainly has shown he possesses.



Cancerlivfonden

In 2021, Cancerlivfonden was dissolved, and in that connection (with permission from the authorities) they allocated part of their remaining assets to Børnecancerfonden. The condition was that the money should be spent on “providing support for spreading awareness and information about cancer.”

Børnecancerfonden received DKK 700,000, and this allows us the opportunity to further develop our “Børnekræft” (translated as “Child Cancer”) app.



Chau Hoi Shuen Foundation Limited, Hongkong

Rune Hostrup lives in Hong Kong with his wife and their two young boys. Here he is working for a local businesswoman who on her 60th birthday decided to give 1 million Hong Kong dollars (approximately DKK 800,000) to charity. Rune was in the lucky position of getting to decide what organisation the money should go to. And he had no doubt: it had to be Børnecancerfonden.

Shortly after Rune and his family arrived in Hong Kong, their friend’s 4-year-old daughter was diagnosed with a brain tumour back home in northern Jutland. The little girl was hospitalised for long periods and had to go through complicated surgeries.

The girl came back home, but life has forever changed for her and her family. And it was with this in mind that Rune earmarked the money for brain tumour research and family support.



Management statement

The Board of Directors and the Executive Management have today approved the annual accounts for the financial year 1 January - 31 December 2021 for Børnecancerfonden.

The annual accounts are submitted in accordance Danish Act on Foundations and Certain Associations, the requirements of the Articles of Association regarding the submission of accounts in accordance with the Danish Financial Statements Act for Account Class A with those adjustments arising from the Foundation's special circumstances and the ISOBRO guidelines for accounts submission by fundraising organisations.

It is our view that the annual accounts provide a true and fair view of the Foundation's assets and liabilities and financial position as of 31 December 2021 and of the result of the Foundation's activities for the financial year 1 January - 31 December 2021 and the allocation of the funds raised.

It is our opinion that the Management Report contains a true and fair description of the issues discussed in the Statement.

No events have occurred after the end of the financial year which could substantially affect the financial position of the Foundation.

Copenhagen, 9 June 2022

CEO



Marianne Benzon Nielsen
Christina E. Høi-Hansen

Board:



(Chairman)



Jens Bjørn Andersen



Thomas Leth Frandsen



Søren Rittig



Michael Reker Schiøth



Morten Stadil



Anja Bisgaard Pinborg

Independent auditor's Audit Statement

To the Board of Directors of Børnecancerfonden Opinion

It is our opinion that the annual accounts provide a true and fair view of the Foundation's assets, liabilities and financial position as of 31 December 2021 and of the result of the Foundation's activities for the financial year 1 January - 31 December 2021 in accordance with the Act on Foundations and Certain Associations, the Articles of Association and the Danish Financial Statements Act for Accounting Class A adapted to the subsidy conditions of the Ministry of Health, including "Auditing instructions for auditing subsidies" and the accounting instructions for project subsidies in excess of DKK 500,000, the "Subsidy provisions".

We have audited the annual accounts for Børnecancerfonden for the financial year 1 January - 31 December 2021, which includes profit and loss account, balance and notes, including accounting policies ("the accounts").

Basis of opinion

We have carried out our audit in accordance with international auditing standards and those additional requirements that apply in Denmark as well as good public auditing practice, and the audit is performed on the basis of the requirements of the subsidy provisions. Our responsibilities in accordance with these standards and requirements are described in detail in the audit statement section "Auditor's responsibilities for auditing the annual accounts". We are independent of the foundation in accordance with International Ethics Standards Board for Accountant's international guidelines for auditors' ethical behaviour (IESBA Code) and the additional ethical requirements that apply in Denmark and we have also complied with our additional ethical obligations in accordance with these requirements and the IESBA Code. It is our opinion that the evidence obtained is sufficient and suitable as the basis for our opinion.

Statement on the Management Report

The management is responsible for the Management Report.

Our conclusion about the annual accounts does not cover the Management Report and we express no firm opinion regarding the Management Report.

In connection with our audit of the annual accounts, it is our responsibility to read the Management Report and in this connection to consider whether the Management Report is substantially inconsistent with the annual accounts or the knowledge obtained by us during the audit or in any other way appears to contain material misinformation.

Our responsibility additionally includes to consider whether the Management Report contains the information required by the Danish Financial Statements Act.

On the basis of the work carried out, it is our opinion that the Management Report is in accordance with the annual accounts and has been prepared in accordance with the requirements of the Danish Financial Statements Act and the Articles of Association. We have not identified material misinformation in the Management Report.

Management's responsibility for the annual accounts

Management is responsible for preparing annual accounts that provide a true and fair view in accordance with the Act on Foundations and Certain Associations, the Articles of Association, and the provisions of the Danish Financial Statements Act for Accounting Class A with the required adaptations and the subsidy provisions. Management is further responsible for the internal controls which Management consider necessary to be able to prepare annual accounts without material misinformation, regardless of whether this is due to fraud or error.

When preparing the annual Accounts, it is the responsible of Management to assess the Foundation's ability to continue as a going concern; to inform about issues regarding going concern where relevant, and; to prepare the annual accounts on the basis of the accounting principles for going concern, unless Management intends to liquidate the Foundation, cease operations, or has no other realistic alternative than to do this.

The Auditor's responsibilities for auditing the annual accounts

Our goal is to obtain a high degree of certainty as to whether the annual accounts overall are without material misinformation, regardless of whether this is due to

fraud or error, and to provide an Audit Statement with an opinion. A high degree of certainty is a high level of certainty, but not a guarantee that an audit carried out in accordance with international auditing standards and the additional requirements applying in Denmark and good public auditing practice, cf. the subsidy provisions, will always uncover material misinformation where such exists. Misinformation may occur as the result of fraud or error, and can be considered material if it can be reasonably expected, individually or in combination, to influence the financial decisions made by users on the basis of the annual accounts.

As part of an audit carried out in accordance with internal auditing standards and those additional requirements that apply in Denmark as well as good public auditing practice, cf. the subsidy provisions, we make professional assessments and maintain professional scepticism during the audit. In addition:

- We identify and assess the risk of there being material misinformation in the annual accounts, regardless of whether this is due to fraud or error, prepare and perform audit actions in response to these risks and obtain evidence which is sufficient and suitable for forming the basis for our opinion. The risk of not detecting material misinformation due to fraud is higher than for material misinformation due to error, as fraud may involve conspiracies, use of forged documents, deliberate omissions, deception, or failing to perform internal controls.
- We obtain an understanding of the internal control where relevant to the audit in order to be able to prepare auditing actions relevant to conditions, but not in order to express an opinion on the efficiency of the Foundation's internal control.
- We consider whether the accounting practice used by Management is appropriate and whether the accounting estimates and associated information prepared by management are reasonable.
- We form an opinion as to whether Management's preparation of the annual accounts based on accounting principles for a going concern are appropriate and whether on the basis of the obtained evidence there is significant uncertainty associated with events or issues that may create substantial doubt about the Foundation's ability to carry on as going concern. If it is our opinion that a significant uncertainty exists, our Audit Statement must point to relevant information in the annual accounts or, if such information is insufficient, we must modify our opinion. Our opinion is based on the evidence obtained until the date of our Audit Statement. Future events or circumstances may, however, result in the Foundation being unable to keep operating.

- We consider the overall presentation, structure, and contents of the annual accounts, including information in notes, and whether the annual accounts reflect the underlying transactions and events in such a way as to provide a true and fair view of them.

We communicate with senior management about, i.a., the planned scope and timing of the audit and material audit-related observations, including any material internal control shortcomings that we may identify during the audit.

Declaration pursuant to other legislation and other regulations. Statement on legality audit and management audit

Management is responsible for actions covered by the financial reporting being in accordance with allocations, legislation, and other regulations as well as with concluded agreements and standard practice and that appropriate financial measures have been taken in managing the funds and activities covered by the accounts.

In connection with our audit of the accounts, it is, in accordance with good public auditing practice and the subsidy provisions, our responsibility to select relevant elements for legality audit and financial management audit. In a legality audit, we test with a high degree of certainty for the elements selected whether the actions covered by the financial reporting are in accordance with the allocations, legislation and other regulations and with concluded agreements and standard practice. In a financial management audit we assess with a high degree of certainty whether the systems, processes, or actions examined support relevant financial considerations to the management of the funds and operation of activities covered by the accounts.

If, on the basis of the work carried out, we are of the opinion that there is cause for material critical comment, we must report this.

We have no material critical comments to report in this connection.

Copenhagen, 9 June 2022
PricewaterhouseCoopers
Statsautoriseret Revisionspartnerselskab
CVR no. 33 77 12 31



Henrik Aslund Pedersen
Certified Public Accountant
mne17120

Profit and loss account

	Note	2021 (DKK)	2020 (DKK)
Public funds (public allocation funds and VAT compensation)	2	2,682,769	2,278,346
Receives donations, legacies and collections	3	28,265,843	28,471,260
Income and donations from events	4	31,511,480	28,564,428
Income from income-generating activities		62,460,092	59,314,034
Legacies reserved for nominal capital		-33,494	-7,248,306
Costs from income-generating activities	5	-9,656,757	-11,055,056
Result from income-generating activities	6	52,769,841	41,010,672
Administration costs	7	-2,673,942	-2,704,743
Earnings before financials		50,095,899	38,305,929
Financial income	8	4,590,212	3,521,264
Financial costs	9	-66,714	-90,624
Earnings before objective-related activities		54,619,397	41,736,569
Family support (holiday cottages, children and youth)		-2,154,820	-2,222,335
Secretariat costs related to research		-982,556	-851,186
Information activities		-441,231	-339,422
Costs from objective-related activities	10	-3,578,607	-3,412,943
Profit/loss for the year		51,040,790	38,323,626
Proposed profit allocation			
Profit/loss for the year		51,040,790	38,323,626
Refunded and lapsed previous allocations		1,160,375	388,990
Reserves for allocation from previous year		11,547,432	6,610,700
Available for allocation		63,748,597	45,323,316
Approved/allocated during the financial year		49,526,937	33,775,884
Reserved for later allocation		14,221,660	11,547,432
Total allocated		63,748,597	45,323,316

Balance sheet as at 31 December

	Note	2021 (DKK)	2020 (DKK)
Assets			
Securities, tied	14	125,126,749	117,675,835
Cash and cash equivalents, tied		406,904	250,290
Balance with disposable assets		-1,921,234	5,652,800
Tied assets		123,612,419	123,578,925
Holiday cottages, Blokhus and Dronningmølle	13	2,896,009	2,890,511
Furniture, equipment and IT	13	70,460	78,250
CRM system	13	839,952	1,306,982
Tangible fixed assets		3,806,421	4,275,743
Deposits		215,953	215,953
Receivables		1,202,022	1,858,457
Receivable tax on dividends		408,278	195,062
Prepaid expenses and accrued income		0	37,500
Balance with tied assets		1,921,234	-5,652,800
Deposits with financial institutions		71,021,272	66,614,604
Disposable assets		78,575,180	67,544,519
Total assets		202,187,599	191,123,444

Balance sheet as at 31 December

	Note	2021 (DKK)	2020 (DKK)
Liabilities			
Nominal capital	15	123,612,419	123,578,925
Tied up capital		123,612,419	123,578,925
Reserved for later allocation	16	14,221,660	11,547,432
Result carried forward	17	0	0
Disposable capital		14,221,660	11,547,432
Total equity		137,834,079	135,126,357
Other debts		755,853	1,274,385
Outstanding expenses		511,906	528,848
Approved outstanding allocations		63,085,761	54,193,854
Debts		64,353,520	55,997,087
Total commitments		64,353,520	55,997,087
Total liabilities		202,187,599	191,123,444
Contingent liabilities, security, etc.	18		
Collection accounts	19		
Accounting policies	20		

Notes

	2021 (DKK)	2020 (DKK)
Note 1 – Collections, Section 8 contributions, donations, gifts and collections		
In 2021, Børnecancerfonden only carried out collections for the foundation's general purpose. The foundation had no earmarked collections or collections for specific purposes and the accounts for the collections for the foundation's general purpose is therefore representative for the annual report.		
Public funds (public allocation funds and VAT compensation), cf. Note 2	2,682,769	2,278,346
Received donations, legacies and collections, cf. Note 3	28,265,843	28,471,260

Notes

	2021 (DKK)	2020 (DKK)
Income and donations from events, cf. Note 4	31,511,480	28,564,428
Financial income (net), cf. Note 8+9	4,523,498	3,430,640
Total income	<u>66,983,590</u>	<u>62,744,674</u>
Legacies reserved for nominal capital	-33,494	-7,248,306
Costs from income-generating activities, cf. Note 5	-9,656,757	-11,055,056
Administration costs, cf. Note 7	-2,673,942	-2,704,743
Family support costs (holiday cottages, children and youth), cf. Note 10	-2,154,820	-2,222,335
Secretariat costs related to research, cf. Note 10	-982,556	-851,186
Costs for awareness campaigns and information, cf. Note 10	-441,231	-339,422
Profit/loss for the year	<u>51,040,790</u>	<u>38,323,626</u>
Refunded and lapsed previous allocations	1,160,375	388,990
Transferred to allocation from previous year	11,547,432	6,610,700
Result before allocations to the purpose	<u>63,748,597</u>	<u>45,323,316</u>
Application, by purpose		
Family support	9,524,803	7,944,284
Research	40,002,134	25,831,600
Information activities	0	0
Allocated this year	<u>49,526,937</u>	<u>33,775,884</u>
Transferred for later allocation	<u>14,221,660</u>	<u>11,547,432</u>
Note 2 – Public funds (public allocation funds and VAT compensation)		
VAT compensation	977,500	599,757
Operating subsidy from public allocation funds 2021	1,705,269	1,678,589
	<u>2,682,769</u>	<u>2,278,346</u>
	2021 (DKK)	2020 (DKK)
Note 3 – Received donations, legacies and collections		
Non-earmarked donations and gifts	7,673,296	7,362,809
Earmarked donations and gifts	9,293,966	6,216,496
Legacies	9,762,222	13,240,838
Collections via social media and Betternow	1,536,360	1,651,117
	<u>28,265,843</u>	<u>28,471,260</u>

	2021 (DKK)	2020 (DKK)
Note 4 – Income and donations from events		
Team Rynkeby	18,237,311	18,163,853
Knæk Cancer	6,500,000	6,000,000
FodboldtrøjeFredag	1,315,694	1,320,054
Gribbolden	1,054,107	1,064,107
SportscarEvent	1,000,000	650,000
Flying Tiger	891,317	0
Danmark Rundt, Team Bodenhoff	535,591	615,120
Stigminoen	508,743	0
Team Ringe	233,000	252,000
GolfRock	220,750	220,200
MakVærket – leather aprons for Scanpan	176,000	0
My Home Møbler – sale of leather handbags	134,645	0
Odendo	127,472	0
Falkonergården Gymnasium og HF	127,454	0
Year 9 at Lindebjergskolen runs for Børnecancerfonden	125,018	0
Danmark for Børnecancerdagen	113,090	0
Støtteforeningen Bingo/Bankø	111,288	279,094
Spring for LIVSKRAFT	100,001	0
	<u>31,511,480</u>	<u>28,564,428</u>

	2021 (DKK)	2020 (DKK)
Note 5 – Costs from income-generating activities		
Direct costs, cf. Note 6	5,525,668	7,408,274
Other external costs	1,189,478	938,620
Staff costs, cf. Note 11	2,941,611	2,708,162
	<u>9,656,757</u>	<u>11,055,056</u>

Note 6 – Result from income-generating activities

	Income	Of which legacies reserved for nominal capital	Direct costs	Distributed costs	Result
2021					
Public funds	2,682,769	0	0	0	2,682,769
Collected private funds	28,265,843	33,494	3,340,801	1,953,395	22,938,153
Income from events	31,511,480	0	2,184,867	2,177,694	27,148,919
	<u>62,460,092</u>	<u>33,494</u>	<u>5,525,668</u>	<u>4,131,089</u>	<u>52,769,841</u>
2020					
Public funds	2,278,346	0	0	0	2,278,346
Collected private funds	28,471,260	7,248,306	5,512,713	1,815,809	13,894,432
Income from events	28,564,428	0	1,895,561	1,830,973	24,837,894
	<u>59,314,034</u>	<u>7,248,306</u>	<u>7,408,274</u>	<u>3,646,782</u>	<u>41,010,672</u>

Note 7 – Administration costs

	2021 (DKK)	2020 (DKK)
Other external costs	1,319,736	1,482,329
Staff costs, cf. Note 11	1,354,206	1,222,414
	<u>2,673,942</u>	<u>2,704,743</u>

Note 8 – Financial income

	2021 (DKK)	2020 (DKK)
Income from tied assets	2,635,205	1,925,759
Realised profit margin on sale of securities	361,953	44,612
Market value adjustment of securities	1,592,774	1,550,893
Value adjustments	50	0
Interest income	230	0
	<u>4,590,212</u>	<u>3,521,264</u>

Note 9 – Financial costs

	2021 (DKK)	2020 (DKK)
Management fees, Danske Bank	66,714	62,358
Value adjustments	0	9,246
Index adjustment, frozen holiday allowance	0	10,304
Interest SKAT	0	8,503
Interest costs	0	213
	<u>66,714</u>	<u>90,624</u>

Note 10 – Costs from objective-related activities

	Family support	Research	Information activities
2021			
Direct costs	429,390	332	102,313
Other external costs	418,048	197,795	77,442
Staff costs, cf. Note 11	1,307,382	784,429	261,476
	<u>2,154,820</u>	<u>982,556</u>	<u>441,231</u>
2020			
Direct costs	433,069	0	10,600
Other external costs	321,188	150,453	95,244
Staff costs, cf. Note 11	1,468,078	700,733	233,578
	<u>2,222,335</u>	<u>851,186</u>	<u>339,422</u>

	2021 (DKK)	2020 (DKK)
Note 11 – Staff costs		
Salaries and wages	6,319,446	6,079,001
Pension contributions ATP	37,205	28,590
Other social costs	76,222	66,253
Education, staff and other staff costs	216,231	159,121
	<u>6,649,104</u>	<u>6,332,965</u>

Staff costs are distributed as follows:

Costs from collections	2,941,611	2,708,162
Family support (La Vida, holiday cottages, children and youth)	1,307,382	1,468,078
Research	784,429	700,733
Information activities	261,476	233,578
Administration costs	1,354,206	1,222,414
	<u>6,649,104</u>	<u>6,332,965</u>
Average number of employees	<u>10.9</u>	<u>8.4</u>

No fees have been paid to the Board of Directors, Science Committee or the volunteers supporting the Foundation. Staff costs are distributed across respective activities based on assessments of the time spent by individual employees.

Note 12 – Tax

The Foundation does not expect to be assessed for tax on the year's result as all collected and allocatable funds are expected to be allocated inside a 5 year period. No tax has been paid in the financial year other than retained dividend taxes.

Note 13 – Tangible fixed assets

	Holiday cottages Blokhus (DKK)	Holiday cottage Dronningmølle (DKK)	Furniture, equipment and IT (DKK)	CRM system (DKK)
Purchase sum, 1 January	4,991,809	2,304,667	228,628	1,425,799
Donations received 1 January	-2,458,050	-2,047,339	0	0
Increase	0	5,498	35,917	11,500
Decrease	0	0	0	0
Purchase sum, 31 December	2,633,183	262,826	264,545	1,437,299
Cumulative depreciation 1 January	0	0	150,378	118,817
Depreciation for the year	0	0	43,707	478,530
Cumulative depreciation 31 December	0	0	194,085	597,347
Book value 31 December	2,633,183	262,826	70,460	839,952
Public property valuation 1 October 2021	3,950,000	1,400,000		

Note 14 – Securities

	2021 (DKK)	2020 (DKK)
Balance 1 January	117,675,835	114,333,492
Increase	30,033,942	7,229,433
Decrease	-24,537,755	-5,482,595
Realised price profit posted under financial income	361,953	44,612
Un-realised price adjustments posted under financial income	1,592,774	1,550,893
Balance 31 December	125,126,749	117,675,835

Securities are measured at market value on the balance sheet date. Daily market value adjustments for the year are included in financial income in the profit and loss account.

Note 15 – Tied equity

Nominal capital:

	2021 (DKK)	2020 (DKK)
Nominal capital at financial year start	123,578,925	116,330,619
Nominal capital increase	33,494	7,248,306
Nominal capital at financial year end	123,612,419	123,578,925

	2021 (DKK)	2020 (DKK)
Note 16 – Reserved for later allocation		
Balance 1 January	11,547,432	6,610,700
Applied during the year	-11,547,432	-6,610,700
Reserved during the year	14,221,660	11,547,432
Balance 31 December	14,221,660	11,547,432

	2021 (DKK)	2020 (DKK)
Note 17 – Disposable equity		
Balance 1 January	0	0
Profit/loss for the year	51,040,790	38,323,626
Carried from reserved to later allocation	11,547,432	6,610,700
Allocations/grants for the year	-49,526,937	-33,775,884
Refunded and lapsed previous allocations	1,160,375	388,990
Reserved for later allocation	-14,221,660	-11,547,432
Balance 31 December	0	0

Note 18 – Contingent liabilities, security, etc.

The lease is non-cancellable by the lessee for 3 years and 6 months from 1 January 2019. Thereafter, the tenant can terminate the lease with 6 months' notice to the end of a month.

The rental obligation for 2022 has been calculated to be DKK 643,188.

Note 19 – Collection accounts

In 2021, Børnecancerfonden has collected funds for the foundation's general purpose by encouraging donations to be made for the Foundation's work via collection boxes and events and via website/donation module, online collection platform, social media, sales/auction, merchandise, mail distribution, text messages, TV, radio, advertising in daily/weekly publications, direct mail, telemarketing, and local collections by volunteers and companies. The funds collected are received via mobile payment solutions and bank transfers.

Børnecancerfonden does not carry out door-to-door collections.

The funds collected are spent on research, information, and direct support for children with cancer and their families.

Børnecancerfonden is approved by Indsamplingsnævnet (permit IN No. 00053).

Børnecancerfonden is approved pursuant to the Danish Tax Assessment Act's Sections 8(A) and 12(3) and therefore covered by the Danish Collection Act's Section 4. Collections are performed in accordance with the Collections Act No. 511 of 26 May 2014 and Executive Order No. 160 of 26 February 2020 and the funds collected are spent on the objectives of the Foundation.

Note 20 – Accounting policies

The annual accounts for Børnecancerfonden are submitted in accordance with the Act on Foundations and Certain Associations provisions on non-commercial charitable foundations and the Articles of Association and the Danish Financial Statements Act provisions for Account Class A with the those adjustments arising from the Foundation's special circumstances and the ISOBRO guidelines for accounts submission by fundraising organisations.

The annual accounts are presented on the basis of the same policies as last year.

General note about recognition and measuring

Assets and liabilities

Assets are valuables owned by the Foundation or monies due the Foundation. Monies due the Foundation are typically accounts receivable where the payment will not be received until after the balance sheet date. Monies due the Foundation also consists of binding undertakings regarding subsidies, legacies or gifts received from third parties before the balance sheet date which will only be paid after the balance sheet date. It can also include costs which have been paid before the balance sheet date which relate to the period after the balance sheet date.

Assets are recognised in the balance sheet when it is likely that future financial benefits will accrue to the Foundation and the value of the assets can be reliably measured.

Liabilities are amounts owed by the Foundation to others, e.g. approved allocations, holiday pay allowance, outstanding A-level taxes, etc., and outstanding expenses. Liabilities are recognised in the balance sheet when the Foundation has a legal or actual obligation and it is likely that future financial benefits will leave the Foundation and the value of the obligation can be reliably measured.

On first recognition, assets and liabilities are measured at cost price. Measuring after first recognition will be carried out as described for each accounting entry below.

Recognition and measuring considers predictable risks and losses which might occur until the presentation of the annual accounts and which can confirm or refute circumstances that existed on the balance sheet date.

Conversion of foreign currency

Transactions in foreign currency are converted at the exchange rates on the transaction date. Gains and losses occurring from differences between exchange rates on the transaction date and exchange rates on the payment date are recognised in the income statement as a financial item. Receivables, debt and other monetary items in foreign currency that have not been settled on the balance sheet day are converted at the exchange rate on the balance sheet date. Differences between the exchange rates on the balance sheet date and transaction date are recognised together with the account entry in question.

Income and costs

Income is amounts which have increased the Foundation's equity, i.e. the value of transactions, events, and the like, which have increased the Foundation's net assets.

Costs is amounts which have been used by the Foundation and therefore have decreased the

Foundation's equity, i.e. the value of transactions, events, and the like, which have decreased the Foundation's net assets. The profit and loss account recognises income as a general rule as it is earned, while costs are recognised by those amounts that relate to the financial year. Recognition is carried out as described for each accounting entry below.

Profit and loss account

Income

Foundation income includes donations in the shape of legacy and gift amounts, collections and the like and income from events. Income is recognised as it is received or when the foundation has received notification of a commitment.

Legacies and willed gifts

Legacies and willed gifts are recognised when final estate inventory is available and the legacy has been received.

Subsidies and income from event collections

Subsidies from public allocation funds and income from event collections are recognised when the Foundation acquires the right to the amounts.

VAT compensation

VAT compensation income relates to VAT refunds on shared costs from the previous year and is recognised in the profit and loss account at the time of receipt.

Financial entries

Financial entries include interest income and costs, share dividends, realised and unrealised price gains and losses related to tied assets and are recognised at the time of receipt.

Costs applied to income-generating activities

Costs related to income-generating activities are recognised in the profit and loss account when they are paid. Usual accrual of costs is performed so as to include the relevant financial years. Costs related to income-generating activities include direct and indirect costs and are assigned to the individual activities based on consumption. Costs consist of costs that are a direct consequence of the activities performed and a distribution of shared costs such as salaries, staff costs, and administration costs following an assessment of the employees' time consumption for the individual activities.

Costs from objective-related activities

Costs spent on objective-related activities are recognised in the profit and loss account when paid and include direct and indirect costs for carrying out objective-related activities such as collection, family support, research, information, and administration. Costs consist of costs that are a direct

consequence of the activities performed and a distribution of shared costs such as salaries, staff costs, and administration costs following an assessment of the employees' time consumption for the individual activities.

Approved allocations

Approved allocations for Børnecancerfonden's objectives decrease the Foundation's disposable funds during the allocation year. Allocations which have not been paid out on the balance sheet date are recognised as debts under the account entry outstanding allocations.

Taxes

The Foundation's taxable income is calculated as the accounting result less allocations and adjusted for non-taxable income and costs. The Foundation aims to allocate each year's collected and allocatable funds no later than inside a 5 year period. The Foundation therefore does not expect to have any tax liability.

Securities

Securities trading on a regulated market are valued at the official market price on the balance sheet date. Realised and un-realised value adjustments are recognised in the profit and loss account.

Furniture, equipment, IT, and fitting out of leased premises

Costs for furniture, equipment, IT, and fitting out of leased premises which present a utility value to the Foundation across a period of several years are depreciated across the utility period as follows:

Office furniture, equipment and IT: 3-5 years
Fitting out of leased premises: 5 years

Holiday cottages

Holiday cottages are recognised in the balance sheet at cost price with a deduction of donations received to purchase the summer cottages and subsequent improvements. The scrap value of the summer cottages is expected to exceed the value recognised in the balance sheet, after which they are not depreciated.

Receivables

Receivables are donations where undertakings have been received before the balance sheet date, but the amount is not received until after the balance sheet date. Receivables are measured at amortised cost price which usually equates to nominal value.

Prepaid expenses and accrued income

Prepaid expenses and accrued income covers costs that have been paid before the balance sheet date, but which relate to the following year.

Equity

The foundation's tied equity consists partly of the original base capital added by the founder and subsequent transfers in the form of gifts, legacies and contributions, the foundation's own consolidation in terms of disposing of results and value adjustment of securities, etc. in the tied assets.

The foundation's disposal capital consists of reserves for later allocation in relation to the allocation of results.

Reserved for later allocation

Reserved for later allocation decreases the Foundation's disposable fund in the reservation year and are spent on allocation in the following year.

Outstanding allocations

Outstanding allocations include amounts approved but not yet paid.

Other debts

Other debts are outstanding A-level tax, labour market (AM) contributions, ATP, and outstanding holiday allowance.

Key figures

Key figures are calculated in accordance with ISOBRO's recommendations. Key figures presented in the Management Report have been calculated as follows:

Key figures	Calculation formula	Key figures express
Profit margin	Result from income-generating activities/ Income from income-generating activities*100	The net profit ratio shows the share of the funds recognised as income that remains after deduction of directly attributable costs for producing the result
Administration percentage	Administration costs/Income from income-generating activities*100	The administration percentage shows the share of the Foundation's total income that was spent, respectively, on administration and similar costs and non-distributable costs
Objective percentage	Costs from objective-related activities/ Income from income-generating activities*100	The objective percentage shows the share of the total income that was spent on objective-related activities
Solvency ratio	Equity/total liabilities*100	The solvency ratio expresses the financial strength of the Foundation



børne cancer fonden

Vester Farimagsgade 1, 3rd floor
DK-1606 Copenhagen V

kontakt@boernecancerfonden.dk

Production: Børnecancerfonden
Graphics and layout: Sunrise
Photo: Tine Harden et al
Printed by: Rosendahls A/S
Translated by: AdHoc Translations